drugset / Trial / NCT00006361

SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

NCT00006361

Treatment

Summary

RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.

Timeline

Start
2000-12
Primary completion
2003-01
Completion

Publications

  • Results Zahalsky AJ, Wong RJ, Lis E, et al.: Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-902, 2002.

Drugs

EvaluationDrugModalityDoseRoute
Subject semaxanib Small molecule Intravenous